T he modern management of heart failure (HF) is predominantly guided by objective assessments of left ventricular ejection fraction (LVEF), which has been shown to be predictive of adverse outcomes even in the absence of symptomatic HF (1) . Historically, patients with HF have been categorized into 2 groups based on their LVEF: heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). This distinction has been important in HF management because of the different demographic characteristics, etiologies, and comorbidities between the 2 groups (2). More importantly, numerous clinical trials have shown that these groups differ in their response to therapies; although a number of medical and device therapies are proven to reduce morbidity and mortality in patients with HFrEF, there have been no therapies thus far that have been proven to improve these outcomes in patients with HFpEF (3).
As the field has steadily characterized important differences between these categories of HF over the Often considered a "gray" area or the "middle child" in HF (7) Notably, the characteristic in which the HFmrEF population was more similar to the HFrEF population was the comorbidity of coronary artery disease (CAD) (8) . These findings were consistent with the clinical profiles seen in other recent studies (11, 14) .
PATHOPHYSIOLOGY OF HFmrEF
Studies suggest that HFrEF and HFpEF are distinct pathophysiological syndromes (15) . 
PROGNOSIS IN HFmrEF
MORTALITY RISKS. Mortality rates are modestly higher among patients with HFrEF but similar between those with HFmrEF and HFpEF. In OPTIMIZE-HF, the mortality rates were 3.9% for patients with HFrEF, 3.0% for HFmrEF, and 2.9% for HFpEF (2) .
Among patients in ADHERE, in-hospital mortality was 4.7% in patients with LVEF <25%, 3.4% in patients with LVEF 25% to 40%, 3.2% in those with LVEF 41% to 54%, and 3.0% in those with LVEF $55% (4). In a Canadian study of hospitalized patients with HF, 
Hsu et al. Cumulative incidence functions for all-cause mortality, all-cause rehospitalization, cardiovascular (CV) rehospitalization, and heart failure (HF) rehospitalization in the heart failure with preserved ejection fraction (HFpEF) (black lines), heart failure with mid-range ejection fraction (HFmrEF) (blue lines), and heart failure with reduced ejection fraction Aldosterone Antagonist) study (23) . In this study of >3,000 patients, there was no effect of spironolactone on the composite primary outcome of cardiovascular death, aborted cardiac arrest, or HF hospitalization; however, there was a reduction in HF hospitalizations in the treatment group (HR: 0.83).
Moreover, there was a significant interaction between treatment and LVEF, with stronger benefit seen in patients with LVEF 45% to 50% (24) . In light of these findings from TOPCAT, the AHA/ACCF recently released an update to its guidelines, adding the Class IIb recommendation that in a selected population of patients with HF with LVEF $45%, aldosterone antagonists may be considered to decrease hospitalizations (25) . 
not found to significantly influence outcomes in patients with LVEF $40% (28). The same findings were observed when the analysis was confined to patients with LVEF 40% to 50%.
In the TIME-CHF (Trial of Intensified Versus Standard Medical Therapy in Elderly Patients With
Congestive Heart Failure), N-terminal proBNP-guided management was found to be improve HF hospitalization-free survival in patients with HFmrEF and HFrEF but not in patients with HFpEF (14) .
However, the GUIDE-IT (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment) trial also used N-terminal proBNP-guided therapy in patients with HFrEF, but this study was terminated prematurely due to futility (29) . The role of biomarkers in the management of HFmrEF thus remains to be determined. General comparisons of the clinical characteristics, outcomes, and guideline-directed medical therapies for each heart failure group. Class of recommendation is denoted in parentheses, if applicable. ACEI ¼ angiotensin-converting enzyme inhibitors; ARB ¼ angiotensin receptor blocker; ARNI ¼ angiotensin receptor-neprilysin inhibitor; BB ¼ beta-blockers; CAD ¼ coronary artery disease; HFmrEF ¼ heart failure with mid-range ejection fraction; HFpEF ¼ heart failure with preserved ejection fraction; HFrEF ¼ heart failure with reduced ejection fraction; MRA ¼ mineralocorticoid receptor antagonist. 
